Literature DB >> 6653884

Expression of hepatitis B surface antigen in yeast.

N Harford, T Cabezon, M Crabeel, E Simoen, A Rutgers, M De Wilde.   

Abstract

The genomes of HBV viruses of two different serotypes were cloned in E. coli. Sequences coding for the major polypeptides of surface antigen (HBsAg) were fused with the 5' end of a cloned yeast arg3 gene. When introduced into yeast, on a suitable vector, the hybrid gene directed the synthesis of a fusion protein. Crude extracts of such strains were shown to contain HBsAg like material having physical properties characteristic of the antigen isolated from the plasma of chronic human carriers, as judged by isopycnic and rate zonal centrifugation. Furthermore, these extracts readily elicit specific anti-HBsAg antibodies in rabbits. Further manipulations of the 5' part of the arg3 gene resulted in the introduction of a unique restriction site located in the 5' non translated leader sequence. The resulting vector was used to construct a recombinant plasmid directing the synthesis of the mature (226 amino acids) HBsAg polypeptide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653884

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  12 in total

1.  Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant.

Authors:  J A Waters; M Kennedy; P Voet; P Hauser; J Petre; W Carman; H C Thomas
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  Immunogenicity of yeast-derived hepatitis B vaccine from two different producers.

Authors:  E Dahl-Hansen; J C Siebke; S S Frøland; M Degré
Journal:  Epidemiol Infect       Date:  1990-02       Impact factor: 2.451

3.  Antibody responses to recombinant and plasma derived hepatitis B vaccines.

Authors:  S E Brown; C Stanley; C R Howard; A J Zuckerman; M W Steward
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-18

Review 4.  Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.

Authors:  Wolfram H Gerlich
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

Review 5.  Heterologous protein production in yeast.

Authors:  G Gellissen; K Melber; Z A Janowicz; U M Dahlems; U Weydemann; M Piontek; A W Strasser; C P Hollenberg
Journal:  Antonie Van Leeuwenhoek       Date:  1992-08       Impact factor: 2.271

6.  Expression of human alpha 1-antitrypsin cDNA in the yeast Saccharomyces cerevisiae.

Authors:  T Cabezón; M De Wilde; P Herion; R Loriau; A Bollen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

Review 7.  Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Authors:  Natasha Kushnir; Stephen J Streatfield; Vidadi Yusibov
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

Review 8.  Medical virology of hepatitis B: how it began and where we are now.

Authors:  Wolfram H Gerlich
Journal:  Virol J       Date:  2013-07-20       Impact factor: 4.099

Review 9.  Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.

Authors:  Joan Kha-Tu Ho; Beena Jeevan-Raj; Hans-Jürgen Netter
Journal:  Viruses       Date:  2020-01-21       Impact factor: 5.048

10.  Elicitation of integrated immunity in mice by a novel pneumococcal polysaccharide vaccine conjugated with HBV surface antigen.

Authors:  Wen Qian; Zhen Huang; Yuqiu Chen; Jinling Yang; Lili Wang; Kai Wu; Min Chen; Nanping Chen; Yongzhong Duan; Jing Shi; Ying Zhang; Qihan Li
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.